Emerging infectious diseases have risen sharply due to population growth, urbanization, travel, trade, and environmental changes, with outbreaks like severe acute respiratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019 highlighting the global need for effective surveillance systems. Various infectious disease surveillance systems are applied depending on the surveillance objectives, target populations, and geographical scope. While Korea has a robust surveillance system, challenges remain in integrating data, enhancing coordination, and improving response efficiency. This article reviews the types and roles of infectious disease surveillance systems through a literature review and proposes strategies for improving Korea’s surveillance system by comparing it with those of other countries, including the World Health Organization (WHO). To strengthen Korea’s surveillance framework, a comprehensive strategy should be implemented to interconnect multiple surveillance mechanisms and enhance real-time data sharing. A centralized data platform must integrate these systems, leveraging artificial intelligence and big data analytics for faster outbreak analysis. International collaboration through data-sharing networks with the WHO, European Center for Disease Prevention and Control, and U.S Centers for Disease Control and Prevention is essential, along with standardized reporting formats to improve interoperability.

Emerging infectious diseases have risen sharply due to population growth, urbanization, travel, trade, and environmental changes, with outbreaks like severe acute respiratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019 highlighting the global need for effective surveillance systems. Various infectious disease surveillance systems are applied depending on the surveillance objectives, target populations, and geographical scope. While Korea has a robust surveillance system, challenges remain in integrating data, enhancing coordination, and improving response efficiency. This article reviews the types and roles of infectious disease surveillance systems through a literature review and proposes strategies for improving Korea’s surveillance system by comparing it with those of other countries, including the World Health Organization (WHO). To strengthen Korea’s surveillance framework, a comprehensive strategy should be implemented to interconnect multiple surveillance mechanisms and enhance real-time data sharing. A centralized data platform must integrate these systems, leveraging artificial intelligence and big data analytics for faster outbreak analysis. International collaboration through data-sharing networks with the WHO, European Center for Disease Prevention and Control, and U.S Centers for Disease Control and Prevention is essential, along with standardized reporting formats to improve interoperability.

Emerging infectious diseases have risen sharply due to population growth, urbanization, travel, trade, and environmental changes, with outbreaks like severe acute respiratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019 highlighting the global need for effective surveillance systems. Various infectious disease surveillance systems are applied depending on the surveillance objectives, target populations, and geographical scope. While Korea has a robust surveillance system, challenges remain in integrating data, enhancing coordination, and improving response efficiency. This article reviews the types and roles of infectious disease surveillance systems through a literature review and proposes strategies for improving Korea’s surveillance system by comparing it with those of other countries, including the World Health Organization (WHO). To strengthen Korea’s surveillance framework, a comprehensive strategy should be implemented to interconnect multiple surveillance mechanisms and enhance real-time data sharing. A centralized data platform must integrate these systems, leveraging artificial intelligence and big data analytics for faster outbreak analysis. International collaboration through data-sharing networks with the WHO, European Center for Disease Prevention and Control, and U.S Centers for Disease Control and Prevention is essential, along with standardized reporting formats to improve interoperability.

Emerging infectious diseases have risen sharply due to population growth, urbanization, travel, trade, and environmental changes, with outbreaks like severe acute respiratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019 highlighting the global need for effective surveillance systems. Various infectious disease surveillance systems are applied depending on the surveillance objectives, target populations, and geographical scope. While Korea has a robust surveillance system, challenges remain in integrating data, enhancing coordination, and improving response efficiency. This article reviews the types and roles of infectious disease surveillance systems through a literature review and proposes strategies for improving Korea’s surveillance system by comparing it with those of other countries, including the World Health Organization (WHO). To strengthen Korea’s surveillance framework, a comprehensive strategy should be implemented to interconnect multiple surveillance mechanisms and enhance real-time data sharing. A centralized data platform must integrate these systems, leveraging artificial intelligence and big data analytics for faster outbreak analysis. International collaboration through data-sharing networks with the WHO, European Center for Disease Prevention and Control, and U.S Centers for Disease Control and Prevention is essential, along with standardized reporting formats to improve interoperability.

The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20,180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.

The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20,180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.

The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20,180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.

The emergence of the omicron variant and its sub-lineages has necessitated vaccine updates for coronavirus disease 2019. In September 2023, the U.S. Food and Drug Administration approved an updated BNT162b2 vaccine targeting the omicron XBB.1.5 variant, which was initiated in Korea in October 2024. This study demonstrates the adverse events reported through active nationwide surveillance after XBB.1.5 vaccination in Korea. Since October 19, 2023, the Korea Disease Control and Prevention Agency has conducted daily Short Message Service surveys to collect data on health issues, fever, vaccination site reactions, systemic symptoms, impact on daily life, and healthcare visits. Among 20,180 respondents, 27.9% reported health issues. Adverse reactions peaked on day 1 (28.7%), including pain at the vaccination site, muscle pain, fatigue, and fever. These findings elucidate the short-term safety of the XBB.1.5 vaccine and support its co-administration with the influenza vaccine, reducing vaccine hesitancy and achieving herd immunity.

Background: The Korea Expert Committee on Immunization Practices (KECIP) is a key advisory body the government to develop guidelines and provide technical advisory activities on immunization policies in Korea. A recent policy study, inspired by global best practices, aims to enhance KECIP's functionality for providing timely and transparent recommendations in the face of evolving vaccine science and emerging infectious diseases like COVID-19. Methods: This study reviewed the current status of KECIP and collected expert opinions through surveys and consultations. Among the 40 panel members who were surveyed, 19 responded to a questionnaire specifically designed to assess the potential areas of improvement within KECIP. Results: The majority of respondents favored maintaining the current member count and emphasized the need for a subcommittee. Opinions varied on issues such as the length of KECIP’s term, the representation of vaccine manufacturers’ perspectives, and the chairperson’s role. However, there was a consensus on the importance of expertise, transparency, and fair proceedings within the committee. Conclusion This study underscores the pivotal role of KECIP in shaping national immunization policies, emphasizing the necessity for informed guidance amidst evolving vaccine science and emerging infectious diseases. Furthermore, it stressed the importance of enhancing KECIP’s capacity to effectively address evolving public health challenges and maintain successful immunization programs in South Korea.

Background: Despite the proven effectiveness of oral antivirals against severe acute respiratory syndrome coronavirus 2 in randomized trials, their clinical reevaluation is vital in the context of widespread immunity and milder prevalent variants. This study aimed to assess the effectiveness of oral antivirals for coronavirus disease 2019 (COVID-19). Methods: This retrospective cohort study utilized a target trial emulation framework to analyze patients with COVID-19 aged 60+ from January to December 2022. Data were obtained from the Korea Disease Control and Prevention Agency and Health Insurance Review and Assessment Service. The study involved 957,036 patients treated with nirmatrelvir/ritonavir and 243,360 treated with molnupiravir, each compared with the matched control groups. Primary outcome was progression to critical COVID-19 requiring advanced respiratory support. Secondary outcomes included progression to severe COVID-19, need for supplemental oxygen, and death within 30 days of the onset of COVID-19.Number needed to treat (NNT) derived from the absolute risk reduction. Results: Nirmatrelvir/ritonavir was significantly associated with a reduced risk of severe (adjusted odds ratio [aOR], 0.823; 95% confidence interval [CI], 0.803–0.843), critical (aOR, 0.560; 95% CI, 0.503–0.624), and fatal COVID-19 (aOR, 0.694; 95% CI, 0.647–0.744).Similarly, molnupiravir reduced the risk of severe (aOR, 0.895; 95% CI, 0.856–0.937), critical (aOR, 0.672; 95% CI, 0.559–0.807), and fatal cases (aOR, 0.679; 95% CI, 0.592–0.779).NNTs for nirmatrelvir/ritonavir were 203.71 (severe), 1,230.12 (critical), and 691.50 (death);for molnupiravir, they were 352.70 (severe), 1,398.62 (critical), and 862.98 (death). Higher effectiveness was associated with older adults, unvaccinated individuals, and the late pandemic phase. Conclusion Nirmatrelvir/ritonavir and molnupiravir are effective in preventing progression to severe disease in elderly adults with COVID-19.